Pancreatic Cancer Research

ResearcherThe University of TokyoActive in the last 2 years

Taku Aoki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2868-5246; OpenAlex author ID A5008241281. Sources: OpenAlex.

Their work

Papers
16 (first author 5, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 4 papers · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 3 papers

Papers 16

  1. Novel modified frailty index predicts completion of adjuvant chemotherapy in resectable pancreatic cancer in a dual center study. Co-author DOI 10.1038/s41598-025-02365-5↗
  2. Immunohistochemical Classification of High-Grade Pancreatic Intraepithelial Neoplasia and Ductal Cancerization in Pancreatic Ductal Adenocarcinoma Using p53, S… Last author DOI 10.1111/apm.70106↗
  3. Postoperative Geriatric Nutritional Risk Index as a Determinant of Tolerance to S-1 Adjuvant Chemotherapy After Curative Surgery for Pancreatic Ductal Adenocar… Co-author DOI 10.3390/cancers17091448↗
  4. Neoadjuvant and Adjuvant Chemotherapy for Pancreatic Adenocarcinoma: Literature Review and Our Experience of NAC-GS. Co-author DOI 10.3390/cancers16050910↗
  5. C-Reactive Protein-to-Albumin Ratio as a Predictive Indicator for Evaluating Tolerability in S-1 Adjuvant Chemotherapy after Curative Surgery for Pancreatic Ca… Co-author DOI 10.3390/cancers16193372↗
  6. Prognostic impact of postoperative infection in patients with pancreatic cancer: A multicenter cohort study. Co-author DOI 10.1016/j.surg.2022.09.002↗
  7. Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00280-021-04267-5↗
  8. Predictors of Poor Pathological Response to Neoadjuvant Gemcitabine Plus S-1 Chemotherapy in Patients With Pancreatic Ductal Adenocarcinoma. First author DOI 10.1097/mpa.0000000000001826↗
  9. Efficacy of Adjuvant Chemotherapy According to the Pathological Response to Neoadjuvant Chemotherapy Among Patients With Pancreatic Ductal Adenocarcinoma. First author DOI 10.21873/anticanres.14925↗
  10. Clinical Predictors of Unresectable Disease at Laparotomy in Patients With Pancreatic Ductal Adenocarcinoma Planning to Undergo Surgical Resection. First author DOI 10.21873/anticanres.15335↗
  11. Clinical Significance of Neoadjuvant Chemotherapy With Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/invivo.11700↗
  12. NK cell and IFN signatures are positive prognostic biomarkers for resectable pancreatic cancer. First author DOI 10.1016/j.bbrc.2017.12.083↗
  13. Adjuvant combination therapy with gemcitabine and autologous γδ T-cell transfer in patients with curatively resected pancreatic cancer. Co-author DOI 10.1016/j.jcyt.2017.01.002↗
  14. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer. Co-author DOI 10.18632/oncotarget.11129↗
  15. Smad4 Decreases the Population of Pancreatic Cancer-Initiating Cells through Transcriptional Repression of ALDH1A1. Co-author DOI 10.1016/j.ajpath.2015.01.011↗
  16. A R0 resection case of initially unresectable metastatic pancreatic cancer downstaged by FOLFIRINOX therapy. Co-author DOI 10.1097/mpa.0000000000000139↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shozo Mori · 6 shared papers, 2019–2024 · strength 0.96
  2. Keiichi Kubota · 6 shared papers, 2019–2024 · strength 0.96
  3. Naotake Funamizu · 3 shared papers, 2024–2025 · strength 0.66
  4. Akimasa Sakamoto · 3 shared papers, 2024–2025 · strength 0.66
  5. Yuzo Umeda · 3 shared papers, 2024–2025 · strength 0.66
  6. Yasutsugu Takada · 3 shared papers, 2024–2025 · strength 0.66
  7. Takayuki Shimizu · 5 shared papers, 2019–2021 · strength 0.60
  8. Takatsugu Matsumoto · 4 shared papers, 2021 · strength 0.51
  9. Yumi Nozawa · 1 shared paper, 2025 · strength 0.33
  10. Norihiro Kokudo · 5 shared papers, 2014–2018 · strength 0.29
  11. Mayumi Hoshikawa · 3 shared papers, 2016–2018 · strength 0.20
  12. Kiyoshi Hasegawa · 3 shared papers, 2016–2018 · strength 0.20
  13. Kazuhiro Kakimi · 2 shared papers, 2017–2018 · strength 0.15
  14. Kenjiro Okada · 1 shared paper, 2022 · strength 0.12
  15. Hiroji Shinkawa · 1 shared paper, 2022 · strength 0.12
  16. Masahiro Iseki · 1 shared paper, 2022 · strength 0.12
  17. Hiroshi Maruyama · 1 shared paper, 2022 · strength 0.12
  18. Masamichi Mizuma · 1 shared paper, 2022 · strength 0.12
  19. Kenichiro Uemura · 1 shared paper, 2022 · strength 0.12
  20. Takashi Suzuki · 1 shared paper, 2019 · strength 0.09
  21. Yoshihiro Sakamoto · 2 shared papers, 2014–2016 · strength 0.08
  22. Hiroyuki Isayama · 2 shared papers, 2014–2016 · strength 0.08
  23. Kazuhiko Koike · 2 shared papers, 2014–2016 · strength 0.08
  24. Yousuke Nakai · 2 shared papers, 2014–2016 · strength 0.08
  25. Yukari Hoshino · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.